2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Please select year

• 11.29
  2023

  Addex Reports Q3 2023 Financial Results and Provides Corporate Update

• 11.28
  2023

  Addex Convenes Extraordinary General Meeting

• 11.23
  2023

  Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

• 11.14
  2023

  Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

• 11.08
  2023

  Addex Regains Nasdaq Listing Compliance

• 11.02
  2023

  Addex Announces Participation in the BIO-Europe 2023 Conference

• 10.20
  2023

  Addex Completes ADS Ratio Change

• 10.06
  2023

  Addex Announces Plan to Implement ADS Ratio Change

• 09.20
  2023

  Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

• 09.06
  2023

  Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

• 09.05
  2023

  Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

• 09.04
  2023

  Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

• 08.10
  2023

  Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

• 08.04
  2023

  Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

• 08.03
  2023

  Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF 2.7 million from Indivior in Extended Substance Use Disorder Research Collaboration

• 07.24
  2023

  Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

• 06.15
  2023

  Addex Increases Issued Share Capital to Create Treasury Shares

• 06.01
  2023

  Addex Shareholders Approve All Resolutions at Annual General Meeting

• 05.18
  2023

  Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

• 05.11
  2023

  Addex Reports Q1 2023 Financial Results and Provides Corporate Update

• 05.10
  2023

  Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

• 05.05
  2023

  Addex Convenes Annual General Meeting 2023

• 05.04
  2023

  Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

• 04.05
  2023

  Addex Completes $5.0 Million Equity Financing

• 04.04
  2023

  Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease

• 04.03
  2023

  Addex Raises $5.0 Million in Equity Financing

• 03.30
  2023

  Addex Reports Full Year 2022 Financial Results and Provides Corporate Update

• 03.28
  2023

  Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

• 03.16
  2023

  Addex Announces Upcoming Conferences it will participate for H1 2023

• 02.09
  2023

  Addex Regains Nasdaq Listing Compliance

• 02.06
  2023

  Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

• 01.19
  2023

  Addex Provides Corporate Update and Financial Guidance

• 12.08
  2022

  Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

• 11.11
  2022

  Addex Reports Q3 2022 Financial Results and Provides Corporate Update

• 11.03
  2022

  Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022

• 11.03
  2022

  Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

• 11.01
  2022

  Addex Increases Issued Share Capital to Create Treasury Shares

• 09.20
  2022

  Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

• 08.18
  2022

  Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update

• 08.15
  2022

  Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

• 08.12
  2022

  Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022

• 07.26
  2022

  Addex Completes $4.2 Million Equity Financing

• 07.22
  2022

  Addex Raises $4.2 million in Equity Financing

• 07.21
  2022

  Addex Provides Corporate Update and Financial Guidance

• 07.21
  2022

  Addex Completes Reduction in Nominal Value of Shares

• 06.17
  2022

  Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

• 05.27
  2022

  Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

• 05.19
  2022

  Addex Announces Participation in the H.C. Wainwright Global Investment Conference

• 05.13
  2022

  Addex Announces Participation in the 22nd Bio€quity Europe Conference

• 05.10
  2022

  Addex Shareholders Approve All Resolutions at Annual General Meeting

• 05.05
  2022

  Addex Reports Q1 2022 Financial Results

• 04.28
  2022

  Addex to Present at the Swiss Biotech Day 2022

• 04.25
  2022

  Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference

• 04.13
  2022

  Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study

• 04.06
  2022

  Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders

• 03.31
  2022

  ADDEX CONVENES ANNUAL GENERAL MEETING 2022

• 03.24
  2022

  Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences

• 03.10
  2022

  Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

• 03.07
  2022

  Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022

• 02.24
  2022

  Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums

• 02.03
  2022

  Addex Increases Issued Share Capital to Create Treasury Shares

• 01.11
  2022

  Addex to Present at the Swiss Equities Baader Virtual Conference

• 01.06
  2022

  Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

• 12.17
  2021

  Addex Raises $10.0 Million in Equity Financing

• 12.15
  2021

  Addex Provides Year End Pipeline Development Update

• 11.18
  2021

  Addex to Present at the Virtual German Equity Forum

• 11.15
  2021

  Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149

• 11.15
  2021

  Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

• 11.04
  2021

  Addex Reports Q3 2021 Financial Results and Provides Corporate Update

• 11.01
  2021

  Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021

• 10.06
  2021

  Addex to Present at the Investors’ Day hosted by Voxia Communication

• 10.04
  2021

  Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors

• 09.29
  2021

  Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm

• 09.29
  2021

  Addex to Present at the Cantor Global Healthcare 2021 Conference

• 09.22
  2021

  CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A

• 09.08
  2021

  Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

• 09.02
  2021

  Addex to Present at the Swiss Biotech Day

• 08.05
  2021

  Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update

• 08.02
  2021

  Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

• 08.02
  2021

  Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

• 07.29
  2021

  Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding

• 07.07
  2021

  Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021

• 07.01
  2021

  Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators

• 06.30
  2021

  Addex Establishes At-The-Market ADS Equity Sale Program

• 06.29
  2021

  Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease

• 06.17
  2021

  Addex Shareholders Approve All Resolutions at Annual General Meeting

• 06.07
  2021

  Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy

• 05.24
  2021

  Addex to Participate at the Benchmark Company Healthcare House Call Conference

• 05.17
  2021

  Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia

• 05.14
  2021

  Addex Convenes Annual General Meeting 2021

• 05.05
  2021

  Addex Reports Q1 2021 Financial Results and Provides Corporate Update

• 05.03
  2021

  Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021

• 04.26
  2021

  Addex Increases Issued Share Capital to Create Treasury Shares

• 04.26
  2021

  Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum

• 04.13
  2021

  Addex to Present at the 20th Annual Needham Virtual Healthcare Conference

• 04.08
  2021

  Addex Files Registration Statement on Form F-3 with the US Securities and Exchange Commission

• 03.11
  2021

  Addex Reports Full Year 2020 Financial Results and Provides Corporate Update

• 03.09
  2021

  Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021

• 03.04
  2021

  Addex to Present at the H.C. Wainwright Global Life Sciences Conference

• 02.17
  2021

  Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

• 02.16
  2021

  Addex GABAB Positive Allosteric Modulators Demonstrate Promise in Alcohol Use Disorder

• 01.21
  2021

  Addex ADX71149 Receives IND Approval to Start a Phase 2a Clinical Study in Epilepsy

• 01.12
  2021

  Addex to Present at the Baader Helvea Swiss Equities Conference

• 01.11
  2021

  Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter’s Option to Purchase Additional Securities

• 01.07
  2021

  Addex Announces Pricing of $10.0 Million Global Offering

• 12.14
  2020

  Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities

• 11.03
  2020

  Addex Reports Q3 2020 Financial Results and Provides Corporate Update

• 11.02
  2020

  Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration

• 11.02
  2020

  Addex to Report Q3 Financial Results and host Conference Call on November 3, 2020

• 09.23
  2020

  Addex to Present at the Investora Conference

• 09.14
  2020

  Addex Therapeutics to Participate at the H.C. Wainwright 22nd Annual Global Investment Conference

• 08.31
  2020

  Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference

• 08.27
  2020

  Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling

• 08.12
  2020

  Addex Reports 2020 Half-Year Financial Results and Provides Corporate Update

• 08.10
  2020

  ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2020 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 12, 2020

• 08.06
  2020

  Addex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020

• 07.20
  2020

  Van Leeuwenhoeck Issues Updated Addex Equity Research Report

• 06.16
  2020

  Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study

• 06.10
  2020

  Addex Shareholders Approve All Resolutions at Annual General Meeting

• 05.20
  2020

  Addex Reports Q1 2020 Financial Results and Provides Corporate Update

• 05.19
  2020

  Addex Therapeutics Establishes Scientific Advisory Board

• 04.08
  2020

  Addex Reports 2019 Full Year Audited Results and Provides Corporate Update

• 04.06
  2020

  Addex Therapeutics to Report 2019 Full Year Audited Results on April 8, 2020

• 03.18
  2020

  Addex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results

• 03.13
  2020

  Addex Therapeutics to Report 2019 Full Year Audited Results on March 19, 2020

• 03.03
  2020

  Addex Therapeutics Appoints Prominent Neuroscience Drug Developer Darryle D. Schoepp PhD as Chairman of its Scientific Advisory Board

• 02.26
  2020

  Addex Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference

• 02.03
  2020

  Addex Therapeutics to Ring the Nasdaq Stock Market Closing Bell

• 01.29
  2020

  Addex Starts Trading American Depositary Shares on Nasdaq Under Ticker ADXN

• 01.13
  2020

  Addex Provides Trading Update and Completes 2019 with Cash Position of CHF31.5 million

• 01.08
  2020

  Addex to Attend 38th Annual J.P. Morgan Healthcare Conference

• 12.20
  2019

  Addex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program

• 12.18
  2019

  ADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES

• 12.03
  2019

  Addex: Van Leeuwenhoeck Issues Update Equity Research Report

• 11.13
  2019

  Addex to Attend Jefferies 2019 London Healthcare Conference

• 11.08
  2019

  Addex to Present at 25th Annual BIO-Europe Conference in Hamburg

• 10.08
  2019

  Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program

• 09.30
  2019

  Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update

• 09.25
  2019

  ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019

• 09.24
  2019

  ADDEX THERAPEUTICS SUBMITS REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSS REPRESENTING SHARES

• 08.27
  2019

  Van Leeuwenhoeck Issues Equity Research Report with Strong Buy and Price Target of CHF11-12 per Share

• 07.09
  2019

  Addex-Led Consortium Receives €4.85 Million Eurostars Grant to Develop Novel Allosteric Modulator to Treat Post-Traumatic Stress Disorder (PTSD)

• 06.20
  2019

  Addex Shareholders Approve All Resolutions at Annual General Meeting

• 05.28
  2019

  Addex Annual General Meeting Scheduled for June 19, 2019

• 05.20
  2019

  Addex Increases Issued Share Capital and Creates Treasury Shares

• 05.08
  2019

  Addex to Present at the 28th Medtech Investing Europe Conference

• 05.06
  2019

  Addex to Present During the Swiss Biotech Day

• 04.30
  2019

  ADDEX REPORTS 2018 FULL YEAR AUDITED RESULTS AND PROVIDES CORPORATE UPDATE

• 04.29
  2019

  Addex to Announce 2018 Full Year Audited Results on April 30, 2019

• 03.21
  2019

  Addex to Participate in the BIOEurope Spring Conference

• 03.11
  2019

  Addex to Present at the Cowen 39th Annual Health Care Conference on March 13, 2019

• 03.08
  2019

  Addex Trading Update in Accordance with Art. 53 of the SIX Listing Rules (Ad hoc publicity)

• 02.14
  2019

  Addex and Indivior to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441

• 01.07
  2019

  Addex Trading Update: Completes 2018 with Strong Cash Position

• 11.22
  2018

  Addex Van Leeuwenhoeck Equity Research Report Highlights Deep Pipeline Well Funded through Pivotal Registration Study and Increases Price Target to CHF 14

• 11.12
  2018

  Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference

• 10.22
  2018

  Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy

• 10.02
  2018

  Addex to Present at the Sachs 18th Annual Biotech in Europe Forum

• 09.28
  2018

  Addex Reports 2018 Half-Year Financial Results and Provides Corporate Update

• 09.25
  2018

  Addex to Present at the Investora Zurich Conference on 27 September

• 09.25
  2018

  ADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR

• 09.20
  2018

  Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust

• 09.04
  2018

  Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD

• 07.12
  2018

  Van Leeuwenhoeck Issues Equity Research Note Highlighting Addex Investment Opportunity

• 06.21
  2018

  Addex Shareholders Approve All Resolutions at Annual General Meeting

• 04.30
  2018

  Addex Reports 2017 Full Year Results and Provides Corporate Update

• 03.29
  2018

  Addex Sucessfully Raises CHF40 million in Capital Increase

• 03.20
  2018

  Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association

• 03.19
  2018

  Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting

• 03.05
  2018

  Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process

• 02.23
  2018

  Addex Publishes Extraordinary General Meeting Invitation

• 02.15
  2018

  Addex Launches CHF40 million Capital Increase with Commitments from Specialist US Healthcare Investors

• 02.07
  2018

  Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management

• 02.05
  2018

  Addex Provides Key Financial Indicators and Trading Update

• 02.02
  2018

  Van Leeuwenhoeck Issues Equity Research Note Highlighting Value of Recent Indivior Strategic Partnership on GABAB PAM

• 01.08
  2018

  Addex Therapeutics Equity Research Report Update Issued by valuationLAB

• 01.03
  2018

  Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments

• 10.18
  2017

  Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share

• 10.03
  2017

  Addex Therapeutics ADX71441 Program Awarded $5.3 Million Grant from US National Institute on Drug Abuse to Support Human Studies for the Treatment of Cocaine Use Disorder

• 09.26
  2017

  Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results

• 09.18
  2017

  Addex Makes Changes to Executive Management

• 06.23
  2017

  Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting

• 06.06
  2017

  Addex Annual General Meeting Scheduled for 22 June 2017

• 05.31
  2017

  Addex Increases Issued Share Capital and Creates Treasury Shares

• 05.09
  2017

  Addex ADX71441 Demonstrates Preclinical Analgesic Effects

• 05.04
  2017

  Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology

• 04.05
  2017

  Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results

• 02.28
  2017

  Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018

• 02.27
  2017

  Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia

• 02.06
  2017

  Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of Neurodegenerative Diseases

• 01.31
  2017

  Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson’s Disease

• 01.09
  2017

  Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain

• 12.13
  2016

  Addex ADX71441 Pharmacological Profile Published in Neuropharmacology

• 11.28
  2016

  Addex Appoints Biopharmaceutical Industry Veteran, Roger G. Mills, M.D., as Chief Medical Officer

• 10.17
  2016

  Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia

• 10.11
  2016

  Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction

• 09.30
  2016

  Addex Therapeutics Reports First Half 2016 Operating Highlights and Financial Results

• 09.20
  2016

  Addex Collaborators Published New Data Supporting the Role of Negative Allosteric Modulators of Follicle Stimulating Hormone and Luteinizing Hormone Receptors in Reproductive Health

• 07.27
  2016

  Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.

• 07.20
  2016

  LifeSci Capital Issues Equity Research Report on Addex Therapeutics

• 06.24
  2016

  Addex Shareholders Approved all Board Proposals at 2016 Annual General Meeting

• 06.13
  2016

  Addex mGluR4 and mGluR7 Programs Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases

• 06.09
  2016

  Addex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction

• 06.08
  2016

  Van Leeuwenhoeck Issues Research Note on Addex Therapeutics

• 06.02
  2016

  Addex Annual General Meeting Scheduled for 23 June 2016

• 06.02
  2016

  Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society

• 05.30
  2016

  Addex Increases Issued Share Capital and Creates Treasury Shares

• 04.29
  2016

  Addex Therapeutics Reports 2015 Financial Results

• 04.11
  2016

  Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

• 03.15
  2016

  Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

• 01.11
  2016

  Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

• 01.04
  2016

  Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

• 12.17
  2015

  Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

• 12.15
  2015

  Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents

• 12.09
  2015

  Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis

• 12.07
  2015

  Addex Moves R&D Operations to Geneva’s Campus Biotech

• 11.25
  2015

  Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program

• 11.23
  2015

  Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases

• 11.19
  2015

  ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share

• 10.13
  2015

  Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder

• 09.30
  2015

  Addex Therapeutics Reports First Half 2015 Financial Results

• 09.23
  2015

  Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy

• 09.08
  2015

  Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field

• 08.17
  2015

  Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics

• 08.14
  2015

  Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s Disease

• 08.05
  2015

  valuationLAB Issues Research Report on Addex Therapeutics

• 07.22
  2015

  Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

• 06.12
  2015

  Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual General Meeting

• 06.03
  2015

  Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain

• 05.29
  2015

  Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia

• 05.27
  2015

  Addex Annual General Meeting Scheduled for 11 June 2015

• 05.07
  2015

  Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inherited Forms of Dystonia

• 04.30
  2015

  Addex Therapeutics Reports 2014 Financial Results

• 03.09
  2015

  Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017

• 02.23
  2015

  Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation

• 02.19
  2015

  Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death

• 01.19
  2015

  Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia

• 01.09
  2015

  Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update

• 01.07
  2015

  Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder

• 12.17
  2014

  Addex Amends mGlu2PAM Collaboration Agreement and Receives USD757,000

• 10.21
  2014

  Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder

• 09.30
  2014

  Addex Therapeutics Reports First Half 2014 Financial Results

• 07.10
  2014

  Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

• 06.30
  2014

  Addex Shareholders Approve All Board Proposals at Annual General Meeting

• 06.12
  2014

  Addex Therapeutics Publishes Annual General Meeting Agenda

• 05.30
  2014

  Addex Therapeutics Publishes Annual Report 2013

• 04.30
  2014

  Addex Therapeutics Reports 2013 Financial Results

• 02.07
  2014

  Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

• 11.04
  2013

  Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

• 10.29
  2013

  Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression

• 10.03
  2013

  Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

• 09.17
  2013

  Addex Therapeutics First Half 2013 Financial Results

• 09.04
  2013

  Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

• 08.09
  2013

  Addex Therapeutics raises CHF3.2 million in a Private Placement to International Institutional Investors

• 05.31
  2013

  Addex Completes Restructuring to Focus on Capturing Potential Upside from its Partnered Asset and CEO Steps Down

• 05.28
  2013

  Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders

• 05.21
  2013

  Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

• 05.02
  2013

  Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study

• 04.30
  2013

  Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role

• 04.30
  2013

  Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence

• 04.24
  2013

  Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441

• 04.22
  2013

  Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

• 04.18
  2013

  Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

• 03.21
  2013

  Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN)

• 03.20
  2013

  Addex Shareholders Approve All Board Proposals at Annual General Meeting

• 03.19
  2013

  Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

• 03.04
  2013

  Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor

• 02.28
  2013

  Addex Therapeutics Reports 2012 Financial Results

• 02.07
  2013

  Addex to Focus Resources on Clinical Pipeline

• 01.29
  2013

  Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia

• 01.22
  2013

  Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441

• 01.07
  2013

  Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

• 12.20
  2012

  Addex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor

• 11.27
  2012

  Addex’ Dipraglurant Named as one of the “Top 10 Neuroscience Projects to Watch” by Windhover and Virginia Herndon

• 11.05
  2012

  Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients

• 10.29
  2012

  Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking

• 10.24
  2012

  Addex Updates Financial Guidance for 2012

• 10.12
  2012

  Addex Therapeutics raises $10 million in a Private Placement to International Institutional Investors

• 10.11
  2012

  Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting

• 10.02
  2012

  Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases

• 09.24
  2012

  Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model

• 09.17
  2012

  Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms

• 08.22
  2012

  Addex Therapeutics First Half 2012 Financial results

• 08.20
  2012

  Addex Therapeutics First Half 2012 Financial Results Next Wednesday

• 07.16
  2012

  Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson’s Disease Pre-Clinical Models

• 07.03
  2012

  Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research

• 06.18
  2012

  Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society’s International Congress

• 06.05
  2012

  Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder with Anxiety Symptoms

• 05.09
  2012

  Addex Shareholders Approve All Board Proposals at Annual General Meeting

• 04.16
  2012

  Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder

• 04.13
  2012

  Addex Takes Steps to Rightsize Operations and Position the Company for Future Success

• 03.21
  2012

  Addex changes name to Addex Therapeutics

• 03.21
  2012

  Addex Reports Positive Top Line Phase IIa Data for Dipraglurant in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)

• 02.23
  2012

  Addex Pharmaceuticals Reports 2011 Financial Results

• 02.21
  2012

  Addex Pharmaceuticals 2011 Financial Results this Thursday

• 02.10
  2012

  Addex to present at the BIO CEO & Investor Conference

• 11.28
  2011

  Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors the addex allosteric modulator platform enabled breakthrough discovery, advancing the understanding of glp-1 mediated gpcr signaling

• 11.02
  2011

  Addex Presents Data on Allosteric Modulators of GPCRs at the Discovery on Target Conference

• 10.24
  2011

  Addex to Present at the BIO Investor Forum in San Francisco

• 10.19
  2011

  Addex to Present in NYC at the Newsmakers in the Biotech Industry conference hosted by BioCentury and Thomson Reuters

• 10.03
  2011

  Addex to Present Progress on Multiple Allosteric Modulator Programs for Neurodegenerative and other Neurological Disorders

• 09.26
  2011

  Addex to Present at the Jefferies 2011 Global Healthcare Conference in London

• 09.02
  2011

  Addex Regains Rights to Parkinson’s Drug Candidates from Merck

• 08.15
  2011

  Addex Pharmaceuticals Appoints Dr Bharatt Chowrira as CEO

• 08.11
  2011

  Addex Pharmaceuticals Announces Board Changes

• 07.27
  2011

  Addex Pharmaceuticals First Half 2011 Financial Results

• 07.20
  2011

  Addex Pharmaceuticals First Half Financial Results on July 27

• 07.07
  2011

  Addex Announces Corporate Reorganization and Restructuring Initiative to Strengthen Its Leadership Position in Allosteric Modulation-Based Drug Discovery and Development Focus on Core R&D Programs

• 06.03
  2011

  Addex Pharmaceuticals CEO Steps Down

• 04.28
  2011

  Addex Shareholders Appoint Hoyoung Huh and Oleg Nodelman to Board, Approve All Board Proposals at Annual General Meeting

• 03.31
  2011

  Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)

• 03.28
  2011

  Addex Partner Starting Clinical Schizophrenia Trial

• 03.14
  2011

  Addex Converts Mandatory Convertible Notes and Issues Ordinary Shares

• 03.09
  2011

  Addex Board Proposes Hoyoung Huh and Oleg Nodelman for Election to the Board of Directors

• 02.23
  2011

  Addex Pharmaceuticals 2010 Financial Results

• 02.18
  2011

  Addex Pharmaceuticals 2010 Financial Results Next Wednesday

• 12.10
  2010

  Addex Awarded EuropaBio’s Most Innovative SME Award

• 11.12
  2010

  Addex Highlights Strength of Allosteric Modulation Technology Platform with Multiple Presentations at Society for Neuroscience 2010

• 09.15
  2010

  Addex Pharmaceuticals Raises CHF20 Million from Biotechnology Value Fund

• 09.08
  2010

  Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to Treat Levodopa-Induced Dyskinesia in Parkinson’s

• 09.02
  2010

  Addex Drug Candidate Effective in Alzheimer’s Disease Model

• 08.25
  2010

  Addex Partner Completes ADX71149 Phase I Program

• 07.28
  2010

  Addex Pharmaceuticals First Half 2010 Financial Results

• 07.21
  2010

  Addex First Half 2010 Financial Results Next Wednesday

• 07.13
  2010

  Addex Drug Candidate Effective in Osteoarthritis Pain Model

• 06.15
  2010

  Addex’s ADX48621 Effective in Preclinical Parkinson’s Disease Studies

• 05.18
  2010

  Addex Executive Management Change

• 05.11
  2010

  Addex R&D Day Highlights

• 04.30
  2010

  Addex Shareholders Approve All Board Proposals at 2010 AGM

• 04.28
  2010

  Addex to Host R&D Day on May 11

• 02.23
  2010

  Addex Pharmaceuticals 2009 Financial Results

• 02.17
  2010

  Addex to Present at The New York Academy of Sciences

• 02.16
  2010

  Addex to Host 2009 Financial Results Call on Feb. 23

• 02.08
  2010

  Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models

• 12.15
  2009

  Development of ADX10059 Ended for Long-term Use

• 12.14
  2009

  Addex Ends Migraine Prevention Study

• 12.02
  2009

  Addex Extends Parkinson’s Disease Collaboration with Merck & Co., Inc.

• 11.24
  2009

  Addex ADX48621 Positive Primate Parkinson’s Data

• 11.16
  2009

  Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial

• 11.03
  2009

  Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference

• 09.28
  2009

  Addex completes enrollment of first mid-stage clinical GERD trial

• 09.17
  2009

  Laurent Massuyeau, Head of Business Development, Resigns

• 09.14
  2009

  Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID)

• 07.28
  2009

  Addex Pharmaceuticals Reports First Half 2009 Financial Results

• 07.23
  2009

  Addex First Half 2009 Financial Results Tuesday, July 28

• 07.16
  2009

  Addex R&D Day Highlights Broadened Therapeutic Potential of Allosteric Modulation Platform to Include Cytokine Receptors as well as GPCRs

• 07.10
  2009

  Addex Achieves Second Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.

• 07.02
  2009

  Addex to Host R&D Day on July 16

• 06.24
  2009

  Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator novel approach has potential for treatment of multiple cns disorders

• 05.27
  2009

  Glutamate Receptor “mGluR5” Implicated in GERD

• 04.29
  2009

  Addex Presents Data on ADX10059 at the AAN

• 04.17
  2009

  Addex Shareholders Approve All Board Proposals at 2009 AGM

• 02.24
  2009

  Addex Pharmaceuticals 2008 Financial Results

• 02.17
  2009

  Addex 2008 Full Year Financial Results Next Tuesday

• 01.28
  2009

  Addex Successfully Completes ADX48621 Phase I Program

• 12.17
  2008

  Addex Starts a Second Phase IIb Trial of ADX10059 in GERD

• 12.17
  2008

  Addex Starts a Phase IIb Trial of ADX10059 for Migraine Prevention

• 12.02
  2008

  Addex Starts Phase IIb ADX10059, Proton Pump Inhibitor Combination Study in GERD Patients

• 11.12
  2008

  GSK Reports Owning 5% of Addex

• 10.15
  2008

  Addex Parkinson’s Product Progressing in Early Clinical Trials

• 09.26
  2008

  GSK Reports Owning 3% of Addex

• 09.10
  2008

  Better Tolerated Formulation of ADX10059 Reduces Acid Reflux

• 08.07
  2008

  Disclosure of Shareholdings in Accordance with Stock Market Rules

• 08.05
  2008

  Disclosure of Shareholdings in Accordance with Stock Market Rules

• 07.28
  2008

  Addex Pharmaceuticals Reports First Half 2008 Financial Results, Maiden Profit

• 07.28
  2008

  Laurent Galibert Appointed Head of Inflammation Business Unit

• 07.18
  2008

  Addex First Half 2008 Financial Results Monday, July 28

• 06.04
  2008

  Addex Starts Phase I ADX10059 Interaction Study

• 05.27
  2008

  Disclosure of Shareholdings in Accordance with Stock Market Rules

• 04.24
  2008

  Addex Starts ADX10059 Phase I Formulation Selection Study

• 04.18
  2008

  Addex Appoints Laurent Massuyeau as Head of Business Development

• 04.18
  2008

  Addex Shareholders Elect Ray Hill to Board of Directors at the 2008 Annual General Meeting

• 03.28
  2008

  Addex Pharmaceuticals R&D Day on April 24

• 03.26
  2008

  Mark Epping-Jordan, Chief Scientific Officer, Resigns

• 03.17
  2008

  Disclosure of Shareholdings in Accordance with Stock Market Rules

• 02.26
  2008

  Addex Pharmaceuticals 2007 Financial Results

• 02.25
  2008

  Addex Achieves First Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.

• 01.03
  2008

  Addex and Merck & Co., Inc. Enter License Agreement to Develop a Drug Candidate for Schizophrenia

• 01.03
  2008

  Addex Announces ADX10059 Phase IIa Acute Anxiety Data

• 12.03
  2007

  Addex and Merck & Co. Collaborate to Develop Drugs for Parkinson’s Disease

• 11.29
  2007

  Addex Pharmaceuticals Confirms Extension of Major Shareholder Lock-up

• 10.29
  2007

  Addex Presents ADX10059 GERD Data at Conference

• 10.01
  2007

  ADX10061 Smoking Cessation Data

• 08.17
  2007

  Addex Pharmaceuticals appoints Head of ADME/PK

• 07.25
  2007

  Addex Pharmaceuticals First Half 2007 Financial Results

• 07.18
  2007

  Addex First Half 2007 Financial Results Next Wednesday

• 05.21
  2007

  Addex Prices IPO Shares at CHF73, raises CHF137 million

• 05.16
  2007

  Addex appoints Head of IR and Communications

• 05.09
  2007

  Addex Launches IPO on SWX Swiss Exchange

• 04.23
  2007

  Addex Pharmaceuticals Plans IPO on SWX Swiss Exchange

• 04.20
  2007

  Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine

• 04.17
  2007

  Addex achieves statistically significant outcome in Phase IIa clinical trial with ADX10059 in Gastro-Esophageal Reflux Disease

• 04.10
  2007

  Addex initiates Phase I trials on ADX48621, a novel compound for treatment of Depression, Anxiety Disorder and Pain

• 01.24
  2007

  Addex starts Phase IIa Proof of Concept Study on ADX10061 for Smoking Cessation

• 12.19
  2006

  Addex begins Phase IIa Proof of Concept Study on ADX10059 for Treatment of Acute Anxiety

• 09.19
  2006

  Addex Pharmaceuticals Raises CHF40 million-SR One and Roche Venture Funds invest in Series C Private Financing

• 08.30
  2006

  Addex commences Phase II clinical trials programme with ADX10059

• 09.22
  2005

  Addex Pharmaceuticals Initiates Phase I Trials with ADX10059, a novel compound intended for Anxiety and Migraine

• 01.26
  2005

  Addex Pharmaceuticals named by tornado insider among europe's top 100 private tech companies

• 01.17
  2005

  Addex Pharmaceuticals enters into Collaboration with Ortho-McNeil Pharmaceutical to Develop Novel Treatments for Anxiety, Depression, Schizophrenia and Alzheimer's disease

• 11.11
  2004

  Addex Pharmaceuticals lauréate du Prix de la Jeune Industrie de Genève

• 05.17
  2004

  Addex Pharmaceuticals Completes Largest ever European Biotech Series B Fund Raising

• 12.10
  2003

  Addex Pharmaceuticals Signs Three year Clinical Development Partnership with Fulcrum Pharma Plc

• 12.18
  2002

  CeNeS Announces Phase II Drug Deal with Addex Pharmaceuticals

• 07.11
  2002

  Addex Pharmaceuticals Attracts Venture Funding From Leading European VC Firms